St Vincent Healthcare
- Type
- Teaching hospital
- Where
- BILLINGS, MT
- Medicare CCN
- 270049
- Received
- $1,241,664 in 201 records, 2021 ($1,950 general, $1,239,714 research)
- Source
- CMS Open Payments search ↗
On this site
- Trademark owner: St. Vincent Healthcare Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 1 | $1,950 |
| 2021 | Research payment | 200 | $1,239,714 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| SEAGEN INC. | 52 | $361,715 | 2021 |
| Merck Sharp & Dohme LLC | 15 | $313,818 | 2021 |
| Genentech, Inc. | 15 | $178,442 | 2021 |
| EMD Serono, Inc. | 46 | $74,967 | 2021 |
| Gilead Sciences, Inc. | 18 | $50,104 | 2021 |
| Ipsen Bioscience Inc. | 8 | $47,793 | 2021 |
| Acerta Pharma LLC | 1 | $47,132 | 2021 |
| PFIZER INC. | 4 | $41,424 | 2021 |
| BeiGene, Ltd. | 18 | $40,921 | 2021 |
| Eli Lilly and Company | 1 | $28,985 | 2021 |
| Aveo Pharmaceuticals, Inc. | 1 | $20,375 | 2021 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $10,074 | 2021 |
| SANOFI US SERVICES INC. | 1 | $7,200 | 2021 |
| E.R. Squibb & Sons, L.L.C. | 2 | $4,878 | 2021 |
| ABBVIE INC. | 2 | $4,792 | 2021 |
| Celgene Corporation | 1 | $2,525 | 2021 |
| Novartis Pharmaceuticals Corporation | 2 | $2,404 | 2021 |
| Pharmacyclics LLC, an AbbVie Company | 9 | $2,160 | 2021 |
| Medtronic, Inc. | 1 | $1,950 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 200 | $1,239,714 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $1,950 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Merck Sharp & Dohme LLC | $27,065 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Che | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $16,226 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $12,755 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $8,412 | Research payment | In-kind items and services | Drug, ONCOLOGY | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Che | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $5,153 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab MK-3475 in Locally Advanced,Metastatic Ren | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $4,359 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $1,962 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2021 |
| 2021-12-23 | Ipsen Bioscience Inc. | $5,508 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Le | 2021 |
| 2021-12-16 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-12-16 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-12-16 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-12-16 | EMD Serono, Inc. | $578 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-12-16 | SEAGEN INC. | $531 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-12-14 | Genentech, Inc. | $7,029 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2021 |
| 2021-12-06 | Bayer Healthcare Pharmaceuticals Inc. | $4,872 | Research payment | Cash or cash equivalent | Non-Covered | BAY 1841788 mHSPC | 2021 |
| 2021-12-06 | Bayer Healthcare Pharmaceuticals Inc. | $1,734 | Research payment | Cash or cash equivalent | Non-Covered | BAY 1841788 mHSPC | 2021 |
| 2021-12-03 | Ipsen Bioscience Inc. | $11,496 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Le | 2021 |
| 2021-12-03 | Ipsen Bioscience Inc. | $6,308 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Le | 2021 |
| 2021-12-03 | Ipsen Bioscience Inc. | $400 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Le | 2021 |
| 2021-11-23 | SEAGEN INC. | $7,721 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-11-23 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-11-23 | EMD Serono, Inc. | $900 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-11-23 | SEAGEN INC. | $596 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-11-18 | Aveo Pharmaceuticals, Inc. | $20,375 | Research payment | Cash or cash equivalent | FOTIVDA Drug, Oncology | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo | 2021 |
| 2021-11-15 | Merck Sharp & Dohme LLC | $58,859 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2021 |
| 2021-11-12 | Merck Sharp & Dohme LLC | $40,584 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalu | 2021 |
| 2021-11-11 | EMD Serono, Inc. | $2,854 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-11-11 | EMD Serono, Inc. | $2,854 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-11-11 | EMD Serono, Inc. | $774 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-11-11 | EMD Serono, Inc. | $260 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-11-09 | SEAGEN INC. | $8,247 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-11-09 | SEAGEN INC. | $8,247 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-11-09 | SEAGEN INC. | $8,247 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-11-09 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-11-09 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-11-09 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-11-09 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-11-09 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-11-09 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-11-03 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-11-03 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-11-03 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-11-03 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-11-03 | Genentech, Inc. | $2,489 | Research payment | Cash or cash equivalent | Kadcyla Biological, BioOncology | TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II | 2021 |
| 2021-10-27 | Genentech, Inc. | $10,850 | Research payment | Cash or cash equivalent | Kadcyla Biological, BioOncology | TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II | 2021 |
| 2021-10-19 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-10-19 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-10-19 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-10-19 | EMD Serono, Inc. | $578 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-10-12 | Genentech, Inc. | $18,430 | Research payment | Cash or cash equivalent | Drug | SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC | 2021 |
| 2021-10-11 | Genentech, Inc. | $14,168 | Research payment | Cash or cash equivalent | Kadcyla Biological, BioOncology | TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II | 2021 |
| 2021-10-07 | PFIZER INC. | $5,400 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESIST | 2021 |
| 2021-09-30 | Ipsen Bioscience Inc. | $14,888 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | An Open-label Randomised Multicentre Phase III Study of Irinotecan Liposome Injection Oxaliplatin 5-fluorouracil/Leucovo | 2021 |
| 2021-09-30 | Ipsen Bioscience Inc. | $2,838 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | An Open-label Randomised Multicentre Phase III Study of Irinotecan Liposome Injection Oxaliplatin 5-fluorouracil/Leucovo | 2021 |
| 2021-09-28 | Genentech, Inc. | $5,000 | Research payment | Cash or cash equivalent | Drug | SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC | 2021 |
| 2021-09-28 | Genentech, Inc. | $4,020 | Research payment | Cash or cash equivalent | Drug | SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC | 2021 |
| 2021-09-27 | SANOFI US SERVICES INC. | $7,200 | Research payment | Cash or cash equivalent | An Open Label Randomized Phase 2 Trial of SAR439859, Versus Endocrine Monotherapy as Per Physician's Choice in Premenopa | 2021 | |
| 2021-09-22 | Merck Sharp & Dohme LLC | $26,241 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanc | 2021 |
| 2021-09-21 | SEAGEN INC. | $28,042 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-09-21 | PFIZER INC. | $16,400 | Research payment | Cash or cash equivalent | BRAFTOVI Drug, ONCOLOGY | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY V | 2021 |
| 2021-09-21 | SEAGEN INC. | $8,247 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-09-21 | SEAGEN INC. | $7,799 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-09-21 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-09-21 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-09-21 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-09-21 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-09-21 | EMD Serono, Inc. | $1,179 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-09-20 | Genentech, Inc. | $27,450 | Research payment | Cash or cash equivalent | Kadcyla Biological, BioOncology | TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II | 2021 |
| 2021-09-16 | Pharmacyclics LLC, an AbbVie Company | $240 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-09-16 | Pharmacyclics LLC, an AbbVie Company | $240 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-09-16 | Pharmacyclics LLC, an AbbVie Company | $240 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-09-16 | Pharmacyclics LLC, an AbbVie Company | $240 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-09-16 | Pharmacyclics LLC, an AbbVie Company | $240 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-09-13 | Genentech, Inc. | $14,168 | Research payment | Cash or cash equivalent | Kadcyla Biological, BioOncology | TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II | 2021 |
| 2021-09-13 | Bayer Healthcare Pharmaceuticals Inc. | $1,734 | Research payment | Cash or cash equivalent | Non-Covered | BAY 1841788 mHSPC | 2021 |
| 2021-09-01 | Genentech, Inc. | $6,140 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2021 |
| 2021-08-25 | Genentech, Inc. | $23,250 | Research payment | Cash or cash equivalent | Drug | GDC 9545 VS SINGLE AGENT ENDOCRINE THERAPY OF PHYSICIAN S CHOICE IN HR 2L 3L MBC | 2021 |
| 2021-08-17 | SEAGEN INC. | $16,098 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-08-17 | SEAGEN INC. | $15,600 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-08-16 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-08-12 | Pharmacyclics LLC, an AbbVie Company | $240 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-08-10 | EMD Serono, Inc. | $8,564 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-08-10 | EMD Serono, Inc. | $8,564 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-08-10 | EMD Serono, Inc. | $260 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-08-10 | EMD Serono, Inc. | $260 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-08-09 | Genentech, Inc. | $18,731 | Research payment | Cash or cash equivalent | Kadcyla Biological, BioOncology | TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II | 2021 |
| 2021-08-04 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-07-26 | Genentech, Inc. | $5,912 | Research payment | Cash or cash equivalent | Kadcyla Biological, BioOncology | TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II | 2021 |
| 2021-07-21 | SEAGEN INC. | $8,247 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-07-20 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-07-20 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-07-20 | EMD Serono, Inc. | $1,179 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-07-19 | Gilead Sciences, Inc. | $4,184 | Research payment | Cash or cash equivalent | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormon | 2021 | |
| 2021-07-19 | Gilead Sciences, Inc. | $1,628 | Research payment | Cash or cash equivalent | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormon | 2021 | |
| 2021-07-15 | Pharmacyclics LLC, an AbbVie Company | $240 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-07-07 | E.R. Squibb & Sons, L.L.C. | $3,708 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices | 2021 |
| 2021-07-01 | Bayer Healthcare Pharmaceuticals Inc. | $1,734 | Research payment | Cash or cash equivalent | Non-Covered | BAY 1841788 mHSPC | 2021 |
| 2021-06-30 | Merck Sharp & Dohme LLC | $18,855 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab ver | 2021 |
| 2021-06-23 | Eli Lilly and Company | $28,985 | Research payment | Cash or cash equivalent | STUDY OF LOXO-305 VERSUS INVESTIGATOR'S CHOICE (IDELAR OR BR) IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LE | 2021 | |
| 2021-06-22 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-06-22 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-06-22 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-06-22 | EMD Serono, Inc. | $1,179 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-06-15 | Pharmacyclics LLC, an AbbVie Company | $240 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-06-15 | Pharmacyclics LLC, an AbbVie Company | $240 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2021 |
| 2021-06-14 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-06-14 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-06-14 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-06-14 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-06-14 | Gilead Sciences, Inc. | $1,591 | Research payment | Cash or cash equivalent | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormon | 2021 | |
| 2021-06-02 | Merck Sharp & Dohme LLC | $53,757 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2021 |
| 2021-06-02 | SEAGEN INC. | $8,247 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-06-02 | SEAGEN INC. | $8,247 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-06-02 | SEAGEN INC. | $8,247 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-05-25 | SEAGEN INC. | $28,273 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-05-25 | SEAGEN INC. | $11,160 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-05-24 | Gilead Sciences, Inc. | $3,182 | Research payment | Cash or cash equivalent | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormon | 2021 | |
| 2021-05-20 | PFIZER INC. | $17,700 | Research payment | Cash or cash equivalent | BRAFTOVI Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUM | 2021 |
| 2021-05-17 | Gilead Sciences, Inc. | $3,787 | Research payment | Cash or cash equivalent | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormon | 2021 | |
| 2021-05-06 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-05-06 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-05-06 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-05-06 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-05-06 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-05-06 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-05-05 | Genentech, Inc. | $1,500 | Research payment | Cash or cash equivalent | Drug | GDC 9545 VS SINGLE AGENT ENDOCRINE THERAPY OF PHYSICIAN S CHOICE IN HR 2L 3L MBC | 2021 |
| 2021-05-03 | Gilead Sciences, Inc. | $3,787 | Research payment | Cash or cash equivalent | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormon | 2021 | |
| 2021-04-30 | BeiGene, Ltd. | $4,634 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine | 2021 |
| 2021-04-30 | BeiGene, Ltd. | $4,634 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine | 2021 |
| 2021-04-30 | BeiGene, Ltd. | $3,108 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine | 2021 |
| 2021-04-30 | BeiGene, Ltd. | $3,108 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine | 2021 |
| 2021-04-30 | BeiGene, Ltd. | $3,108 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine | 2021 |
| 2021-04-30 | BeiGene, Ltd. | $3,108 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine | 2021 |
| 2021-04-30 | BeiGene, Ltd. | $3,108 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine | 2021 |
| 2021-04-30 | BeiGene, Ltd. | $3,108 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine | 2021 |
| 2021-04-30 | BeiGene, Ltd. | $2,260 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine | 2021 |
| 2021-04-30 | BeiGene, Ltd. | $2,260 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine | 2021 |
| 2021-04-30 | BeiGene, Ltd. | $1,695 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine | 2021 |
| 2021-04-30 | BeiGene, Ltd. | $1,695 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine | 2021 |
| 2021-04-30 | BeiGene, Ltd. | $1,130 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine | 2021 |
| 2021-04-30 | BeiGene, Ltd. | $1,130 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine | 2021 |
| 2021-04-30 | BeiGene, Ltd. | $847 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine | 2021 |
| 2021-04-30 | BeiGene, Ltd. | $847 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine | 2021 |
| 2021-04-30 | BeiGene, Ltd. | $565 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine | 2021 |
| 2021-04-30 | BeiGene, Ltd. | $565 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine | 2021 |
| 2021-04-27 | SEAGEN INC. | $13,057 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-04-27 | SEAGEN INC. | $7,987 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-04-27 | SEAGEN INC. | $7,987 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-04-27 | SEAGEN INC. | $531 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-04-21 | SEAGEN INC. | $8,247 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-04-21 | SEAGEN INC. | $8,247 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-04-21 | SEAGEN INC. | $8,247 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-04-20 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-04-20 | EMD Serono, Inc. | $1,179 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-04-20 | ABBVIE INC. | $536 | Research payment | Cash or cash equivalent | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 | |
| 2021-04-19 | Gilead Sciences, Inc. | $1,591 | Research payment | Cash or cash equivalent | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormon | 2021 | |
| 2021-04-12 | Gilead Sciences, Inc. | $396 | Research payment | Cash or cash equivalent | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormon | 2021 | |
| 2021-04-12 | Gilead Sciences, Inc. | $283 | Research payment | Cash or cash equivalent | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormon | 2021 | |
| 2021-04-09 | Ipsen Bioscience Inc. | $3,115 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Le | 2021 |
| 2021-04-08 | ABBVIE INC. | $4,256 | Research payment | Cash or cash equivalent | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 | |
| 2021-04-01 | EMD Serono, Inc. | $2,854 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-04-01 | EMD Serono, Inc. | $2,854 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-04-01 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-04-01 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-04-01 | EMD Serono, Inc. | $1,179 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-04-01 | EMD Serono, Inc. | $377 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-04-01 | EMD Serono, Inc. | $260 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-04-01 | EMD Serono, Inc. | $43 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-04-01 | EMD Serono, Inc. | $43 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-04-01 | EMD Serono, Inc. | $43 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-03-29 | Gilead Sciences, Inc. | $1,591 | Research payment | Cash or cash equivalent | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormon | 2021 | |
| 2021-03-25 | Medtronic, Inc. | $1,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 770G System Device, Durable Pump | 2021 | |
| 2021-03-25 | SEAGEN INC. | $531 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-03-22 | SEAGEN INC. | $8,247 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-03-22 | Gilead Sciences, Inc. | $4,340 | Research payment | Cash or cash equivalent | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormon | 2021 | |
| 2021-03-22 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-03-22 | SEAGEN INC. | $4,101 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-03-22 | Gilead Sciences, Inc. | $578 | Research payment | Cash or cash equivalent | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormon | 2021 | |
| 2021-03-18 | EMD Serono, Inc. | $1,179 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-02-25 | Acerta Pharma LLC | $47,132 | Research payment | Cash or cash equivalent | CALQUENCE Drug, Oncology | A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in | 2021 |
| 2021-02-24 | Novartis Pharmaceuticals Corporation | $2,024 | Research payment | Cash or cash equivalent | KISQALI Drug, ONCOLOGY | RIBOCICLIB STANDARD ENDOCRINE THERAPY IN PATIENTS WITH HR HER2 EARLY BC AT HIGH AMP INTERMEDIATE RISK FOR RECURRENCE | 2021 |
| 2021-02-22 | SEAGEN INC. | $14,277 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-02-22 | Gilead Sciences, Inc. | $4,572 | Research payment | Cash or cash equivalent | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormon | 2021 | |
| 2021-02-22 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Che | 2021 |
| 2021-02-19 | Genentech, Inc. | $19,305 | Research payment | Cash or cash equivalent | Drug | CLL 1L FIT GV FCR BR | 2021 |
| 2021-02-19 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-02-19 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-02-17 | E.R. Squibb & Sons, L.L.C. | $1,170 | Research payment | Cash or cash equivalent | SPRYCEL Drug, Oncology | Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receivi | 2021 |
| 2021-02-12 | Ipsen Bioscience Inc. | $3,239 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Le | 2021 |
| 2021-02-10 | Celgene Corporation | $2,525 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | Connect MDS/AML | 2021 |
| 2021-02-09 | PFIZER INC. | $1,924 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2021 |
| 2021-02-08 | Gilead Sciences, Inc. | $4,509 | Research payment | Cash or cash equivalent | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormon | 2021 | |
| 2021-02-08 | Gilead Sciences, Inc. | $3,787 | Research payment | Cash or cash equivalent | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormon | 2021 | |
| 2021-02-08 | Gilead Sciences, Inc. | $1,017 | Research payment | Cash or cash equivalent | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormon | 2021 | |
| 2021-02-08 | Novartis Pharmaceuticals Corporation | $380 | Research payment | In-kind items and services | KISQALI Drug, ONCOLOGY | RIBOCICLIB STANDARD ENDOCRINE THERAPY IN PATIENTS WITH HR HER2 EARLY BC AT HIGH AMP INTERMEDIATE RISK FOR RECURRENCE | 2021 |
| 2021-01-25 | Gilead Sciences, Inc. | $2,697 | Research payment | Cash or cash equivalent | Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormon | 2021 | |
| 2021-01-21 | EMD Serono, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 | |
| 2021-01-21 | EMD Serono, Inc. | $1,179 | Research payment | Cash or cash equivalent | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of | 2021 |
The latest 200 records of 201.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Billings, MT, county Yellowstone County, MT, state Montana; placed by its city name.
| Measure | Place (city or town) Billings, MT | County Yellowstone County, MT | State Montana |
|---|---|---|---|
| Population B01003 | 119,434 | 168,957 | 1,116,875 |
| Population, 2020 census P1 | 117,116 | 164,731 | 1,084,225 |
| Median age B01002 | 38.8 | 39.0 | 40.4 |
| Under 18 B01001 | 22.0% | 23.0% | 21.0% |
| 65 and over B01001 | 18.8% | 18.3% | 20.1% |
| Households B11001 | 50,994 | 69,897 | 458,859 |
| Foreign born B05002 | 2.1% | 1.9% | 2.3% |
| Median household income B19013 | $73,712 | $76,570 | $72,509 |
| Median family income B19113 | $99,619 | $99,949 | $92,794 |
| Per capita income B19301 | $43,934 | $43,898 | $41,711 |
| Poverty rate B17001 | 9.8% | 9.2% | 11.5% |
| Unemployment rate B23025 | 3.5% | 3.4% | 3.6% |
| Civilian labor force B23025 | 63,477 | 88,987 | 568,568 |
| Mean commute (minutes) B08013 | 16.5 | 18.6 | 19.1 |
| Bachelor's degree or higher B15003 | 36.9% | 34.1% | 35.2% |
| Housing units B25001 | 54,346 | 74,239 | 528,419 |
| Owner-occupied B25003 | 64.8% | 69.6% | 69.2% |
| Renters B25003 | 35.2% | 30.4% | 30.8% |
| Median home value B25077 | $343,400 | $349,500 | $375,800 |
| Median gross rent B25064 | $1,138 | $1,131 | $1,081 |
| White, not Hispanic B03002 | 82.5% | 83.4% | 83.6% |
| Black B03002 | 0.4% | 0.4% | 0.4% |
| Hispanic or Latino B03002 | 7.4% | 6.6% | 4.6% |
| Asian B03002 | 0.8% | 0.7% | 0.8% |
| American Indian and Alaska Native B03002 | 3.9% | 3.6% | 5.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Billings, MT.
Comments